Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing
ConclusionsThis is the first study demonstrating that twice/day insulin glargine reduced the rate of predose hyperglycemia without increasing the risk of hypoglycemia in critically ill patients. A large randomized study is needed to confirm the safety and efficacy of twice/day glargine in the critically ill.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Marlena A. Fox,
Melanie C. Perry,
Xi Liu ‐DeRyke Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Heart | Insulin | Intensive Care | Lantus | Study